Revenue and net profit both hit record highs in 2025, with strong growth in pharmaceuticals, health products, and TCM resources. R&D investment surged, cash dividends reached 90% of net profit, and the company maintained a robust asset structure while advancing digital and international strategies.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.